Elanco Companion Animal Health has announced that its Duvaxyn IE and IE-T Plus vaccines have been licensed for active immunisation against OIE recommended clade 1 and clade 2 equine influenza strains, the first vaccines to be so licensed.
The company says the updated license is a result of a recent challenge study which demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to induce cross protection against clade 2 strain A/equi-2/Richmond/1/07 (H3N8) two weeks after two doses of the primary course1 were given. Cross-protection was further supported by another study2 measuring serum antibody response to the Richmond '07 strain 52 weeks after the three dose primary vaccination course.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade3.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health UK, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of our challenge study and subsequent licence update provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE has identified as being of concern.
"Further reassurance is also given with the confirmation in our study that Duvaxyn IE-T Plus elicits a cell mediated immune response, recognised to play an important role to aid in viral clearance and further enhances protection against strains circulating in the field." 4
The live virus challenge study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two doses of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Duvaxyn IE-T Plus is the only inactivated whole virus carbomer adjuvanted equine influenza vaccine in the UK. According to Elanco, experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins including the conserved nucleoprotein, which shows no antigenic drift, in the vaccine5.
References
Petplan Equine has announced the finalists for the fifth annual Petplan Equine Vet of the Year Award.
The winner of the award award, which is sponsored by Petplan Equine in association with Horse & Rider magazine, will be announced at the annual Animal Health Trust Equestrian Awards, being held at London's Lancaster Hotel on Thursday 1st November, 2012.
The finalists are:
Jess Hill BVM&S MRCVS Woodlands Veterinary Clinic, Cheltenham, Glos, EnglandJess, who qualified in 2003 at the University of Edinburgh Royal (Dick) School for Veterinary Studies, is described as simply "brilliant" for her outstanding calm, capable and kind approach to her work and the way in which she makes herself readily available to her clients. One nomination typifies all those received in praise of Jess' work: "She is incredibly knowledgeable and dedicated and nothing is too much trouble. She is great with horses - always quiet, kind and gentle. She works quickly and confidently, doesn't suggest unnecessary expensive procedures and is always cheerful and a pleasure to be with."
Keith Chandler BVMS Cert EP MRCVS, Kessock Equine Vets, Inverness, ScotlandKeith Chandler, a senior partner at Kessock Equine Vets received several nominations which credited not only him personally for his dedication, knowledge, pragmatic and caring approach but also his practice for its outstanding customer service. Upon receiving news of his nomination, Keith was swift to praise his team and explained: "This nomination reflects the exceptional team I have around me - together we strive to offer continuity, consistency and a minimum level of care to all our clients irrespective of which vet is in attendance."
Lee Paul, BSC BVM&S Cert EP MRCVS, Bushy Equine, Gwaelod-y-Garth, WalesNominations for Lee Paul, a specialist in internal and stud medicine who qualified at Edinburgh University's Royal Dick Veterinary School in 2002, unanimously praised his willingness to 'never give up' and to go beyond the call of duty. He is said to be highly dedicated and is praised for his willingness to always be available such as on the occasion when a horse he had been treating for a swelling in her throat presented complications during a weekend when he was not on duty. Despite this Lee, who had been contacted by the duty vet for background information, attended the call himself within an hour complete with the stethoscope he'd collected from the surgery en route and with his family in his car!
This year's judges were David Stickles, Head of Fund Raising at the Animal Health Trust, Alison Bridge, Editor of Horse & Rider magazine, Ben Mayes, President of the British Equine Veterinary Association (BEVA) and Gil Riley, 2009 Petplan Equine Vet of the Year.
Petplan says that the record number of high calibre nominations made it hard for the judges to choose three finalists. Isabella Von Mesterhazy, Head of Marketing for Petplan Equine said: "Anyone motivated to nominate their vet for this award must hold them in extremely high regard so once again we were very impressed by both the quality and quantity of nominations we received. It is heartwarming and inspiring to read the submissions that describe the outstanding contributions made by all the nominees in keeping owners happy and horses healthy. It has not been easy to select just three to go through to the final."
The winner will be posted on www.petplanequine.co.uk on Friday 2 of November.
Boehringer Ingelheim Vetmedica has released data which shows that one third of laminitic middle aged horses (between the ages of 10 and 15 years) test positive for PPID (Cushing's)1.
Over 3,100 horses were tested for Cushings as part of the company's 'Talk about Laminitis' campaign during the spring.
Liz Barrett, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Although the common perception is that PPID is a disease of only older horses and ponies, the ageing process is progressive and this data from over 330 participating veterinary practices1 indicates that horses and ponies in the 10 to 15 age bracket are also frequently affected."
The company is urging veterinary surgeons to test laminitic or foot-sore horses for PPID this autumn, as this is when there is a greater difference between horses with PPID and those free of the disease2, 3. In support of this, Boehringer will be re-launching its disease awareness initiative 'Talk About Laminitis', with free ACTH blood tests* during September, October and November. To participate in the scheme, veterinary surgeons can download free ACTH blood test vouchers from http://www.talkaboutlaminitis.co.uk/.
Dr Catherine McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS from the University of Liverpool, said: "It is very important to test horses for PPID the first time they present with laminitis because what we want to avoid is recurrence of that laminitis. If it does reoccur, the damage will be worse and the chances of that horse having a successful long-term recovery will be diminished."
For further information on 'Talk About Laminitis', PPID or Prascend, visit www.talkaboutlaminitis.co.uk, contact your Boehringer territory manager or call 01344 746959.
Pfizer Animal Health, maker of the equine wormers Equest & Equest Pramox, has launched Stable Mate, a new app to help horse owners manage their daily equine healthcare regime and get maximum enjoyment from their horse.
Pfizer says the new app has been described by testers as 'undoubtedly the best equestrian electronic management system you could wish for'. It includes an organiser in which to keep horses' records and details of their management requirements. It also includes Track My Ride, a GPS mapping and exercise planning service, and a news feed direct from Horse & Hound.
Stable Mate allows users to keep records for up to six horses on their iPhone. They just need to enter the information needed to keep track of each horse's health routine, including worm control, vaccinations, dentistry, farriery and feeding regime. The app then creates a calendar of events, appointments and reminders designed to make it easy for owners to keep their horse's essential healthcare needs on course.
Records can be passed to a yard manager or friends when the owner goes on holiday, making a temporary transfer of care straightforward. Stable Mate also offers general equine health advice, from the essentials of pasture management to understanding vaccination protocols.
Track My Ride is a GPS navigation system that allows owners to map the route, duration and speed of each ride. Pfizer says it's a great device for planning and monitoring exercise programmes, that owners can use it to explore new hacking routes safely and that they'll never have to worry about finding their way back to their horse box again when hunting or doing a long distance ride. Details of each ride are stored in a history log and can be shared with friends through social media.
Paul Blanc, Pfizer's equine brand manager said: "We have tried to develop an app that is all about the horse and their owner, making it as easy as possible for owners to keep their equine health care on track as well as add to the fun and pleasure with their horse. Stable Mate has well and truly surpassed our expectations. We hope that owners and riders find Stable Mate useful and enjoyable."
Stable Mate is currently available only for iPhone with Android and Blackberry coming soon.
Stable Mate is available free from the iPhone App Store http://itunes.apple.com/us/app/stable-mate/id532341393?ls=1&mt=8. To find out more visit www.wormingyourhorse.info.
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
Merial has launched a limited trial pack version of Equioxx® (firocoxib), the company's COX-2 specific NSAID for horses, which contains 10 tubes of the oral paste.
According to the company, Equioxx is the only equine NSAID that is highly COX-2 selective, acting to reduce pain and inflammation whilst preserving the natural physiological effects of the COX-1 enzyme, at therapeutic levels.
The company also claims that field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.
Jim Tipp BVSc MRCVS, partner at Shropshire based Fyrnwy Equine Clinics said: "As a COX-2 specific NSAID it is not only a good analgesic, but is also an excellent anti-inflammatory. In addition, the COX-1 sparing properties of Equioxx are beneficial where there is increased risk of ulceration."
Equioxx is also available as a low dose injectable solution. For more information contact Merial Customer Services on 0870 6000 123.
Vetoquinol has announced the launch of Chrysanphyton, the latest addition to its range of Equistro feeding stuffs for horses.
Vetoquinol says Chrysanphyton is recommended for horses where support of a normal blood flow to the hoof is important. It contains Chrysantellum americanum, blackcurrant and hazelnut extracts which, according to the company, provide a rich source of nutrient bioflavanoids and vitamins.
The recommended administration of Chrysanphyton is 10ml twice a day in horses (500kg) and 5ml twice a day in ponies with the 1000ml pack lasting 50 or 100 days respectively.
A product information sheet is available on the Equistro website www.equistro.co.uk
For further information contact your local Vétoquinol Territory Manager.
Pfizer Animal Health's Equine Herpes Virus (EHV) vaccine (Duvaxyn EHV 1,4) has been rebranded Equip EHV 1,4).
Pfizer says that EHV is carried by most horses in the UK1 and can cause respiratory disease, abortion and more rarely neurological disease. However, it is the more common sub-clinical infections that pose the most apparent issue for the competition client, with the associated loss of performance and the potential effect on the health of the whole yard.
Once infected with EHV, a horse can harbour the virus throughout its life and potentially shed the disease to other animals without showing any outward signs. According to the company, vaccinating helps to minimise the severity of the disease itself and importantly, can also help to reduce the amount of infective virus that is shed to other in-contact horses.
Equip EHV 1,4 is given as a primary course of two vaccinations, 4-6 weeks apart followed by a single dose every six months. It can also be used as an aid in the control of EHV-1 abortion - pregnant mares should be vaccinated with a single dose during each of the 5th, 7th and 9th months of pregnancy.
For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients contact your Pfizer Account Manager or Pfizer Animal Health, Walton Oaks, Tadworth, Surrey KT20 7NS.
Reference
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142.
Ceva Animal Health has produced a leaflet to help horse owners understand the cause, diagnosis and management of equine back pain.
The company says the management of back pain in the horse can be a particular challenge to vets and a source of frustration for owners. Early diagnosis is likely to be associated with a more favourable outcome but it's important to ensure that other causes of pain and poor performance such as lameness, are not contributing to the horse's clinical signs.
'Understanding back pain' explains the anatomy of the back, as well as the clinical signs of back pain, and how it is diagnosed, including the treatment options and the general prognosis. Copies of the new leaflet are available, free of charge, from your Ceva sales representative. Leaflets on 'Understanding bone spavin', 'Understanding navicular disease', 'Understanding sacroiliac disease' and 'Equidronate discharge instructions', are also available.
For further information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
A team of top equine vets is aiming to raise £125,000 for the Society for the Protection of Animals Abroad (SPANA) by travelling 3000 miles through Europe by motorbike between 22nd August and 9th September.
Sponsored by Elanco Animal Health, the seven-strong team is planning to travel through Belgium, the Netherlands, Germany, Switzerland, France, Italy, Morocco and Spain and deliver lectures to eight European and African veterinary schools in just two weeks.
Led by Professor Derek Knottenbelt from the University of Liverpool, the team also includes Professor Josh Slater from Royal Veterinary College, Dr John Burford from the University of Nottingham, Dr Caroline Hahn from the University of Edinburgh, Dr Michael Hewetson from the University of Helsinki, Ms Joanne Suthers from the University of Liverpool and Dr Edmund Hainisch from the University of Vienna. They are being supported by Jeremy Hulme, chief executive of SPANA, Nic Van Gelder, fundraising and supporter care administrator at SPANA and Cerian Stephens.
All money raised will provide SPANA with diagnostic and surgical equipment for the charity's veterinary clinics for working animals in Mali and Mauritania and for the further development of the Bamako Disabled Riding Centre in Mali.
Mike Brown, Elanco's UK and Ireland country director said: "We are delighted to be sponsoring the Vets with Horsepower European Tour which will raise vital funds for working animals in some of the world's poorest countries. This is just one of the many worthwhile initiatives we are supporting in 2012 which focus on alleviating world hunger, spearheading agricultural leadership, enhancing the human-animal bond and caring for the environment."
For further information on the Vets with Horsepower European Tour visit www.spana.org/horsepower.
ProteqFlu, the live attenuated canarypox equine influenza (EI) vaccine, has had its shelf life extended from 27 to 36 months.
Merial says the increased shelf life is the result of ongoing investment in vaccine research & development, and that the new data underpins the stability of modified live vaccine technology.
Merial highlights that ProteqFlu is the only equine flu vaccine in Europe to include the updated American clade 1 Ohio/03 strain in accordance with the OIE recommendations (2004).
The Federation of European Equine Veterinary Associations (FEEVA) and the European Federation of Farriers Associations (EFFA) have announced that they have joined forces to promote best practice in farriery.
The initiative is the result of recognition by both organisations that equine welfare is best served with the use of only properly trained farriers, working closely with veterinary surgeons as and when needed.
The organisations say that the main aims of the new partnership include:
The President of FEEVA, Professor Josh Slater said: "We look forward to working together at European level and encouraging member associations to do the same at national level, with the primary intention of enhancing equine health through first class farriery."
New research published in the Equine Veterinary Journal (EVJ) has shown that the use of standing sedation to repair lower limb fractures in racehorses produces similar results to surgery performed under a general anaesthetic, but with the advantages of less surgical complexity, time, cost and risk.
The study Short and long term results following standing fracture repair in 34 horses was conducted by Richard Payne and Polly Compston at Rossdales Equine Hospital1.
Standing fracture repair in the horse is a relatively new surgical procedure with very little follow-up data available. Treatable fractures sustained by racehorses in the UK have traditionally been repaired under general anaesthesia but it is well known that this carries an increased risk of anaesthetic-related death compared with other elective surgical procedures. However, despite the substantial increase in the number and type of surgical procedures performed under standing sedation over the past decade there has previously been very little work undertaken on standing fracture repairs.
The study looked at the case records of 34 Thoroughbred and Arab racehorses that had a lower limb fracture surgically repaired by one surgeon at Rossdales up until June 2011. The injuries included non-displaced fractures of the proximal phalanx, the third metacarpal bone and the third metatarsal bone, all of which are relatively common fracture sites in racehorses. Hospital records, owner and trainer telephone questionnaires and website research were used to evaluate follow-up. The short and long-term results were similar to those of horses undergoing repair of comparable fracture configurations under general anaesthesia, with 20 of the horses returning to racing within an average of 226 days.
This early research indicates potential for tangible benefits, including avoidance of the inherent risks of general anaesthesia as well as a reduction in surgical complexity and associated costs, leading the way for future research into larger cohorts of horses.
EVJ's Editor Celia Marr said: "The recent fatalities at the Grand National highlight that it is critical that the equine veterinary research community strives to reduce the prevalence of fractures in our racehorses. We also need to continue to seek better ways of treating those horses that do develop fractures and, while not every fracture will be amenable to this approach, this study is an important first step towards treating some of the non-displaced fractures that occur in racehorses without the need for anaesthesia."
1Short and long term results following standing fracture repair in 34 horses Richard Payne and Polly Compston, Equine Veterinary Journal ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00569.x
Pfizer Animal Health, maker of the equine wormers Equest and Equest Pramox, has unveiled www.wormingyourhorse.info, a new website which aims to make it easier for horse owners to understand and follow the most up-to-date principles of sustainable worm control.
Based on the company's Manage, Test, Plan, Dose campaign, Pfizer says the new website is designed to take the confusion out of equine worm control with clear, logical and easy-to-understand guidance and advice.
The four main sections use diagrams and text to explain how and why it's important to manage the worm challenge on the pasture; the role of faecal worm egg counts (FWECs); how history and management play a part in planning the best worm control programme and how to choose and use the right wormer at the right time of year.
There's an interactive and educational parasite page that shows the parasites that can affect the health of your horse. There are click through buttons on parts of the horse's anatomy revealing details about the appearance of each particular parasite, their lifecycle and the symptoms they can cause. In addition there's a section on frequently asked questions which provides no-nonsense answers to some of the most commonly asked questions about worm control.
Paul Blanc, Pfizer's equine brand manager said: "In developing our new website we have listened carefully to what horse owners really want and need to know. The result is a source of plain-speaking, unbiased facts and advice, providing horse owners with the most current thinking on sustainable worm control in a format they can really identify with."
Pfizer Animal Health is offering the chance to win £500 worth of CPD vouchers to UK veterinary surgeons who participate in the company's 5 minute online survey about Equine Herpes Virus (EHV).
Pfizer says the intention of the survey is to find out more about veterinary perceptions and understanding of this endemic disease and its effects on the UK's valuable equine industry. There are five multi-choice questions and the survey is available online from now until 31st May 2012. Vets who show their prowess in the skills-based section of the survey will be entered to win £500 of British Equine Veterinary Association CPD vouchers.
The survey is part of Pfizer's EHV awareness campaign to help vets encourage horse owners, yard managers, trainers and breeders to keep their horses protected from the effects of this common but often under-prioritised disease. The campaign includes the provision of information leaflets and the coordination of talks to help people, who manage horses, understand the severity of EHV and the best ways to prevent it.
According to Pfizer, the prevalence of EHV can be as high as 87.5% in the UK and latent infections in horses are frequently re-activated.1,2 The consequences can be serious, with abortion outbreaks proving to be a significant economic burden to owners, trainers and breeders.3,4 However, subclinical infections, although usually regarded as less serious, can remain unrecognised and can cause suboptimal performance in horses.
Sporadic, mild respiratory disease caused by EHV can lead to interrupted training and movement restrictions.4 Even after clinical recovery from EHV-1 or upper respiratory tract infections caused by EHV-4, some horse may develop 'poor performance syndrome'.5 These can all have serious financial repercussions on the equine industry.
To take part in the survey, visit http://www.ehvaware.com/. For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients please contact your Pfizer Account Manager.
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142. 2. Allen GP. 2002. Respiratory Infections by Equine Herpesvirus Types 1 and 4. In: P. Lekeux ed. 2002. Equine Respiratory Diseases. New York: International Veterinary Information Service. 3. Garré B et al. Vet Microbiol. 2007; 122(1-2): 43-51. 4. Lunn DP et al. J Vet Intern Med. 2009; 23(3): 450-61. 5. Slater, J. 2007. Equine Herpesvirus. In: Sellon, D. and Long, M. Equine Infectious Diseases. St Louis: Saunders. 144.
The London Fire Brigade has donated a life-size horse model to the Royal Veterinary College, to be used for student training.
The donation is in recognition of 11 years large animal handling training that the RVC has given firefighters from the London Fire Brigade.
The model horse has been named "Fireman Sam" by the students. Fireman Sam was officially presented to Vivienne Heys, the member of staff who organised and participated in the training throughout the entire 11 years, and to student trainers Vikki Wyse and Emma Howson, by London Fire Brigade Group Manager Andy Cane, Station Manager Mark Spier and Watch Manager Jim Wennell .
Andy Cane said how valuable the training has been for the London firefighters and how much the crews have enjoyed their visits to the Royal Veterinary College.
Vivienne emphasised that this programme would not have been possible without the students who have given their time on Wednesday afternoons to help firefighters learn the skills required when working with horses and cattle, and she also praised the staff who have volunteered their time and skills to keep this programme running for 11 years.
Endell Veterinary Group Equine Hospital in Wiltshire has stationed an equine veterinary surgeon on the Isle of Wight permanently to ensure that the island's numerous horses can receive rapid treatment when they need it.
Florus Oskam MRCVS is providing a routine and emergency mobile ambulatory service around the island 24 hours a day. Florus also has the back up of mainland ambulatory vets who also spend time on the Island. Appointments with specific vets to visit the island can also be arranged.
Florus said: "We have been providing a veterinary service on the Isle of Wight for the past 30 years and have a very loyal client base. For years they have been asking us for a permanent service on the island and we are delighted to be able to provide it at last."
Anita Niccolls, dressage rider and trainer on the Isle of Wight, added: "It's very reassuring to know that a vet of Florus's calibre is now resident on the Island and that we are able to have continuity of vet care should a horse need further treatment at the practice's equine hospital in Salisbury."
Kruuse has announced that it has become the exclusive distributor for VideoMed GmbH and its range of veterinary endoscopes and documentation systems.
VideoMed produces a range of equine and small animal endoscopes, gastroscopes and laryngoscopes that multifunction with a flexible documentation console. This provides a mobile capability to file, frame and forward digital and dicom images for review and referral diagnosis.
According to Kruuse, VideoMed products are synonymous with the very highest quality of design, function and reliability that have been developed through years of close working relationship with veterinary professionals. An after care and repair service is also provided by the company for its own and a range of other scopes.
Kruuse says the Overground scope gives a mobile, high resolution, recordable image that clearly determines functional and morphological abnormalities of the larynx, pharynx and upper respiratory system (see image right).
Andrew Groom, Managing Director, Kruuse UK Ltd., said: "This exciting agreement will further enhance our equine and small animal presence within the veterinary industry to bring even more leading edge technology to our customers."
For more information, visit www.kruuse.com and http://www.videomed-gmbh.de/
Picture courtesy of:Neil Townsend MSc BVSc Cert ES (Soft Tissue) DipECVS MRCVSClinician in Equine Soft Tissue SurgeryPhilip Leverhulme Equine Hospital
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
Researchers at the University of Saskatchewan's Western College of Veterinary Medicine (WCVM) are carrying out a survey of equine practitioners to discover, amongst other things, just how common Cushing's disease is internationally.
The 16-question survey was launched this month and will be available for a further six months at www.wcvm.com/veterinarians/cushings_survey.php
Dr. James Carmalt, an equine surgeon and associate professor in the WCVM's Department of Large Animal Clinical Sciences said: "Our objective is to determine the true prevalence of Cushing's disease worldwide, because until now, previous surveys were only based in the U.S."
Dr. Carmalt is also a PhD student in equine neurophysiology through the western Canadian veterinary college's Department of Veterinary Pathology. He and his graduate supervisor, veterinary pathologist Dr. Andrew Allen, are beginning to explore a new treatment methodology for equine Cushing's disease.
Researchers will use practitioners' responses to the brief survey to determine the incidence of the disease and the most common treatment protocols being used by practitioners in countries around the world. They also want to evaluate the need for developing new treatment methodologies. Dr Carmalt said: "Right now, the only available treatment for Cushing's disease requires daily dosing of medications for the rest of the horse's life. It's onerous, time consuming and a huge management challenge.
"If the responses from this survey reflect our impression that practitioners need a new option to offer their clients, our ultimate goal is to develop a one-time treatment for the disease so daily medications for Cushing's disease become unnecessary."
For more information about the Cushing's disease survey for equine practitioners, please contact Dr. James Carmalt (james.carmalt@usask.ca). As part of the survey, practitioners can also provide their email addresses if they wish to receive a copy of the survey results.
Protek Biochem Ltd., a company set up by champion horse-rider Debbie Topping, has won the rights to sell Envirocair Veterinary, a new range of disinfectants and sanitisers targeted at dogs, cats and other domestic pets, as well as horses and farm animals.
The product is claimed to kill 99.99% of all viral, bacterial and fungal infections, and lasts for 14 days.
Debbie said: "I did not consider myself a businesswoman, just a normal horse-rider and animal lover. However, I was so impressed when I tried Envirocair Veterinary that, when I was offered the opportunity to become the main UK distributor, I jumped at the chance."
According to the company, the product is being used by a number of the horses and trainers heading to the London Olympics in 2012. It is now being rolled out across the rest of the UK's animal care sector.
Debbie says that veterinary surgeons, farmers, dog kennels, animal rescue centres, breeders and others will all be able to benefit from the new product: "Envirocair Veterinary doesn't harm skin or irritate the respiratory tract, so you don't need to get dressed up in special clothing every time you use it.
"Used properly, it quite literally kills the threat of major animal diseases such as parvovirus in dogs, which can otherwise be fatal in less than 72 hours.
"It's not an exaggeration to say that Envirocair will protect the health and even save the lives of countless numbers of animals across the UK."
Debbie signed the distribution agreement with the manufacturer Biotech International Ltd last month, before officially launching Envirocair Veterinary this week.
For more information on Protek Biochem Ltd or Envirocair Veterinary, visit http://www.protekbiochem.com/.
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the antibody responses of unvaccinated Thoroughbred weanlings following primary vaccination with Duvaxyn IE-T Plus, Equilis Resequin, Equip FT, Equilis Prequenza Te and ProteqFlu Te.
In addition, following the first vaccination, 43% of the weanlings failed to seroconvert. However, amongst those vaccinated with Duvaxyn IE-T Plus a 100% response rate was observed. The failure rate amongst vaccines other than Duvaxyn IE-T Plus ranged between 7.7% and 78.6%. By the time of the third vaccination (31 weeks after the first) all horses had responded to vaccination.
The study, conducted by the Irish Equine Centre in Johnstone, the Department of Life Sciences at the University of Limerick and the Department of Statistics at Trinity College in Dublin, involved 66 unvaccinated Thoroughbred weanlings on four different stud farms. Following primary vaccination (V1, V2 and V3) with the five vaccines antibody responses were monitored for six months post V3 by single radial haemolysis. Elanco says that the correlation between SRH antibody levels and protection has been well-established and accepted2.
Elanco also highlights a recent study3 which it says demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course. The company says that this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "Most studies carried out by vaccine companies take place under controlled conditions that are optimal for effective vaccination. This latest study shows how well Duvaxyn IET plus stimulates immunity under field conditions against both vaccinal and non-vaccinal strains. Importantly, all the weanlings vaccinated with Duvaxyn seroconverted after the first vaccination, conferring earliest and most reliable protection for these vulnerable animals."
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 779881.
References:
Veterinary practices are being urged to raise awareness of summer skin conditions, such as sweet itch, following research carried out by Elanco Companion Animal Health, distributor of Cavalesse, which revealed that vets only tend to be consulted after horse owners have tried to manage the condition themselves (73%), or if the clinical signs have become severe (67%), potentially leading to major welfare implications.
According to the research, this is despite the fact that over half (55%) of owners of a horse with sweet itch showed concern that their horse will suffer, and nearly half being stressed about the way the condition will affect it (47%). While many horse owners are fairly knowledgeable about the causes of sweet itch and its clinical signs, over a quarter of respondents (26%) did not start managing the condition before the midge season in the spring, which may make managing the condition more frustrating. Nearly a third (31%) stated that they had to curtail their activities with their horse due to welfare, aesthetic and behavioural issues, such as head shaking, rubbing, unpredictability and aggression.
Ed Whittle, technical consultant at Elanco Companion Animal Health said: "86% of those questioned considered sweet itch to be a very serious welfare issue if left untreated, with the worst aspects of the condition being the suffering and distress caused by the constant irritation which affects the quality of life of the horse. Over half (55%) felt that sweet itch had adversely affected the behaviour of their horse, making them difficult to handle or ride. Veterinary practices should be proactively talking to their clients about summer skin conditions such as sweet itch to help alleviate the suffering and distress caused by this frustrating disease."
Elanco says it will be joining forces with the British Horse Society (BHS), The Blue Cross, The Horse Trust, Redwings Horse Sanctuary and World Horse Welfare (WHW) to raise awareness of summer skin conditions, such as sweet itch, during Sweet Itch Awareness Month (SIAM) in March. The campaign will highlight the preventative measures that should be carried out to help alleviate sweet itch and the importance of management of the condition before the start of the midge season in the spring.
Lee Hackett, head of welfare at the BHS, said: "The results of this survey show just how important raising awareness of sweet itch is. All of us, whether we are welfare organisations or vets, need to play our part in educating owners about sweet itch in the hope that they will seek expert advice at an earlier stage and reduce the number of horses that suffer as a result of this condition."
Kerry Taylor, education officer at The Blue Cross, said: "The Blue Cross is pleased to be supporting the sweet itch campaign to raise awareness of the physical and mental impact this condition has on horses. During our May 2011 National Equine Health Survey, skin problems came out the top syndrome affecting horses, and we continue to see many horses coming into our care suffering from sweet itch. Prevention and early treatment is key to managing the potentially debilitating condition."
For further information on sweet itch, Sweet Itch Awareness Month or Cavalesse, please visit http://www.fidavet.com/, or contact Elanco Companion Animal Health, Lilly House, Priestley Road, Basingstoke, RG24 9NL, 01256 353131.
Sweet itch - effect on horse and owner. Mo Gannon & Associates. Web survey in November 2011. 351 responses - owners who have owned horses with sweet itch in the last two years.
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”